

David J Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3713082/publications.pdf>

Version: 2024-02-01

155
papers

7,476
citations

61857

43
h-index

56606

83
g-index

165
all docs

165
docs citations

165
times ranked

7168
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
2	Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2108-2116.	1.8	389
3	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
4	Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients. <i>Circulation</i> , 1998, 97, 2213-2221.	1.6	270
5	The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. <i>Circulation</i> , 2009, 120, 2529-2540.	1.6	247
6	High-Calorie-Expenditure Exercise. <i>Circulation</i> , 2009, 119, 2671-2678.	1.6	171
7	Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients. <i>Diabetes</i> , 1993, 42, 1-7.	0.3	164
8	Platelet Reactivity Characterized Prospectively. <i>Circulation</i> , 2001, 104, 181-186.	1.6	147
9	Factors Contributing to Increased Platelet Reactivity in People With Diabetes. <i>Diabetes Care</i> , 2009, 32, 525-527.	4.3	146
10	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	1.0	131
11	Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells. <i>Diabetes</i> , 1992, 41, 890-895.	0.3	128
12	Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. <i>American Journal of Cardiology</i> , 2003, 92, 1362-1365.	0.7	115
13	Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1979-1989.	1.1	113
14	wnt3a but not wnt11 supports self-renewal of embryonic stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 789-795.	1.0	110
15	Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. <i>American Journal of Cardiology</i> , 2002, 89, 647-650.	0.7	92
16	Differential Effects of Anticoagulants on the Activation of Platelets Ex Vivo. <i>Circulation</i> , 1997, 96, 2877-2883.	1.6	92
17	Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. <i>American Journal of Cardiology</i> , 2000, 85, 491-493.	0.7	91
18	Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 178-188.	1.2	89

#	ARTICLE	IF	CITATIONS
19	Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1777-1783.	1.1	75
20	Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. <i>American Journal of Cardiology</i> , 2003, 91, 334-336.	0.7	71
21	Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. <i>Coronary Artery Disease</i> , 1996, 7, 813-818.	0.3	69
22	Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. <i>Circulation</i> , 2011, 124, 695-703.	1.6	69
23	Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. <i>American Journal of Cardiology</i> , 2002, 90, 1421-1423.	0.7	68
24	Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 435-442.	1.1	68
25	PAI-1 and Diabetes: A Journey From the Bench to the Bedside. <i>Diabetes Care</i> , 2012, 35, 1961-1967.	4.3	67
26	Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein. <i>Journal of the American College of Cardiology</i> , 1999, 33, 261-266.	1.2	66
27	Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: A potential contributor to cardiovascular risk. <i>American Journal of Kidney Diseases</i> , 2002, 40, 315-322.	2.1	66
28	Changes in Arterial Expression of Fibrinolytic System Proteins in Atherogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3294-3301.	1.1	61
29	Antiplatelet therapy: glycoprotein IIb/IIIa antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 672-682.	1.1	60
30	Pharmacodynamic effects during the transition between cangrelor and prasugrel. <i>Coronary Artery Disease</i> , 2015, 26, 42-48.	0.3	60
31	Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. <i>Cardiology Clinics</i> , 2004, 22, 511-526.	0.9	57
32	Cardiovascular complications in diabetes mellitus. <i>Current Opinion in Pharmacology</i> , 2005, 5, 143-148.	1.7	57
33	The effect of plasminogen activator inhibitor type 1 on apoptosis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1037-1040.	1.8	55
34	Effect of Combination Glipizide/GITS/Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2002, 25, 2123-2128.	4.3	53
35	Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. <i>Coronary Artery Disease</i> , 2005, 16, 473-476.	0.3	51
36	Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. <i>American Journal of Cardiology</i> , 1999, 84, 203-207.	0.7	50

#	ARTICLE	IF	CITATIONS
37	Differences between Activation Thresholds for Platelet P-Selectin and Glycoprotein IIb-IIIa Expression and Their Clinical Implications. <i>Thrombosis Research</i> , 1999, 95, 75-82.	0.8	50
38	The Effect of Weight Loss and Exercise Training on Flow-Mediated Dilatation in Coronary Heart Disease. <i>Chest</i> , 2011, 140, 1420-1427.	0.4	50
39	Dependence of Augmentation of Arterial Endothelial Cell Expression of Plasminogen Activator Inhibitor Type 1 by Insulin on Soluble Factors Released From Vascular Smooth Muscle Cells. <i>Circulation</i> , 1997, 96, 2868-2876.	1.6	48
40	Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherosclerosis. <i>Atherosclerosis</i> , 1997, 131, 187-194.	0.4	46
41	Identification and Localization of a Fatty Acid Response Region in the Human Plasminogen Activator Inhibitor-1 Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2696-2701.	1.1	46
42	Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1). <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 1091-1099.	1.3	44
43	Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. <i>American Journal of Cardiology</i> , 2004, 94, 725-728.	0.7	44
44	Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatid compared with bivalirudin. <i>Thrombosis Research</i> , 2006, 118, 361-369.	0.8	44
45	Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 13, 161-165.	1.0	42
46	Platelet-white blood cell (WBC) interaction, WBC apoptosis, and procoagulant activity in stored red blood cells. <i>Transfusion</i> , 2011, 51, 1086-1095.	0.8	41
47	The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle cell proliferation in vivo. <i>Atherosclerosis</i> , 1999, 143, 245-251.	0.4	39
48	Endothelial dysfunction and inflammation after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 94, 1420-1423.	0.7	38
49	Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. <i>American Journal of Cardiology</i> , 2003, 91, 876-878.	0.7	37
50	Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. <i>American Journal of Cardiology</i> , 2004, 93, 6-9.	0.7	36
51	Systemic Inflammation After Drug-Eluting Stent Placement. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 87-92.	1.0	34
52	Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 944-949.	4.3	34
53	Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 25-31.	1.0	33
54	Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. <i>Coronary Artery Disease</i> , 2004, 15, 471-475.	0.3	33

#	ARTICLE	IF	CITATIONS
55	Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy. <i>Journal of the American College of Cardiology</i> , 2011, 57, 685-687.	1.2	33
56	A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart. <i>Experimental Biology and Medicine</i> , 2009, 234, 246-254.	1.1	32
57	The effect of plasminogen activator inhibitor type 1 on apoptosis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1037-40.	1.8	31
58	Novel, Bedside, Tissue Factor-Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy. <i>Circulation</i> , 2000, 102, 2051-2057.	1.6	29
59	Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1559-1563.	0.4	29
60	Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation. <i>Journal of Interventional Cardiology</i> , 2015, 28, 415-419.	0.5	29
61	Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. <i>American Journal of Cardiology</i> , 2003, 91, 1346-1349.	0.7	28
62	Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. <i>American Journal of Cardiology</i> , 2003, 92, 924-929.	0.7	28
63	Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs. <i>Circulation</i> , 2007, 116, 305-315.	1.6	28
64	Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. <i>Histochemistry and Cell Biology</i> , 2007, 128, 135-145.	0.8	28
65	Determinants of coronary vascular disease in patients with type ii diabetes mellitus and their therapeutic implications. <i>Clinical Cardiology</i> , 1997, 20, 433-440.	0.7	27
66	Platelet phenotype changes associated with breast cancer and its treatment. <i>Platelets</i> , 2016, 27, 703-711.	1.1	26
67	Effect of a Computerized Referral at Hospital Discharge on Cardiac Rehabilitation Participation Rates. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2009, 29, 365-369.	1.2	25
68	Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin. <i>Thrombosis and Haemostasis</i> , 2001, 85, 309-313.	1.8	24
69	Altered Expression of Troponin T Isoforms in Mild Left Ventricular Hypertrophy in the Rabbit. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 2345-2354.	0.9	23
70	Attenuation of Accumulation of Neointimal Lipid by Pioglitazone in Mice Genetically Deficient in Insulin Receptor Substrate-2 and Apolipoprotein E. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 603-610.	1.3	23
71	Effect of diabetes on the coagulation and fibrinolytic systems and its implications for atherogenesis. <i>Coronary Artery Disease</i> , 1992, 3, 26-32.	0.3	22
72	Insulin resistance increases PAI-1 in the heart. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 102-107.	1.0	22

#	ARTICLE	IF	CITATIONS
73	Development of glycoprotein IIb/IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 903-913.	0.6	19
74	Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. <i>Coronary Artery Disease</i> , 2006, 17, 471-476.	0.3	19
75	Blood gene expression signatures associate with heart failure outcomes. <i>Physiological Genomics</i> , 2011, 43, 392-397.	1.0	19
76	Effect of Exercise Training and Weight Loss on Platelet Reactivity in Overweight Patients With Coronary Artery Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2013, 33, 371-377.	1.2	19
77	Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease. <i>American Journal of Cardiology</i> , 2000, 85, 784-786.	0.7	17
78	Abciximab-Associated Pseudothrombocytopenia. <i>Circulation</i> , 2000, 101, 938-939.	1.6	17
79	Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. <i>Coronary Artery Disease</i> , 2001, 12, 245-253.	0.3	17
80	Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 171-176.	1.0	17
81	Delineation of the evolution of compositional changes in atheroma. <i>Histochemistry and Cell Biology</i> , 2002, 118, 59-68.	0.8	17
82	Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. <i>Life Sciences</i> , 2006, 79, 1600-1605.	2.0	17
83	Effects on platelet function of a direct acting antagonist of coagulation factor Xa. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 291-296.	1.0	17
84	Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. <i>Coronary Artery Disease</i> , 1993, 4, 713-720.	0.3	16
85	Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. <i>Coronary Artery Disease</i> , 2009, 20, 100-105.	0.3	16
86	The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. <i>American Journal of Cardiology</i> , 1999, 83, 770-774.	0.7	15
87	Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. <i>Coronary Artery Disease</i> , 2016, 27, 65-69.	0.3	15
88	Relation of Leukocytosis to C-Reactive Protein and Interleukin-6 Among Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2005, 96, 538-542.	0.7	14
89	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 465-479.	1.6	14
90	The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. <i>Coronary Artery Disease</i> , 2005, 16, 401-405.	0.3	13

#	ARTICLE	IF	CITATIONS
91	The Independence of Signaling Pathways Mediating Increased Expression of Plasminogen Activator Inhibitor Type 1 in HepG2 Cells Exposed to Free Fatty Acids or Triglycerides. <i>International Journal of Experimental Diabetes Research</i> , 2002, 3, 109-118.	1.0	12
92	A novel dual staining method for identification of apoptotic cells reveals a modest apoptotic response in infarcted mouse myocardium. <i>Histochemistry and Cell Biology</i> , 2007, 128, 275-283.	0.8	12
93	Immunoelectron Microscopic Localization of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Smooth Muscle Cells from Morphologically Normal and Atherosclerotic Human Arteries. <i>Ultrastructural Pathology</i> , 1997, 21, 527-536.	0.4	11
94	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 8-13.	1.0	11
95	Gender-Dependent Differences in Echocardiographic Characteristics of Murine Hearts. <i>Echocardiography</i> , 2008, 25, 739-748.	0.3	11
96	Influence of Preparative Procedures on Assay of Platelet Function and Apparent Effects of Antiplatelet Agents. <i>American Journal of Cardiology</i> , 2007, 100, 722-727.	0.7	10
97	Induction of platelet white blood cell (WBC) aggregate formation by platelets and WBCs in red blood cell units. <i>Transfusion</i> , 2008, 48, 1099-1105.	0.8	10
98	Cardiac ramifications of cocaine abuse. <i>Coronary Artery Disease</i> , 1991, 2, 267-274.	0.3	9
99	Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. , 1998, 44, 257-264.		9
100	Augmentation of Megakaryocyte Expression of Fc γ R11a by Interferon γ . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1138-1143.	1.1	8
101	The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 38-45.	1.0	8
102	Change of energy expenditure from physical activity is the most powerful determinant of improved insulin sensitivity in overweight patients with coronary artery disease participating in an intensive lifestyle modification program. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 672-679.	1.5	8
103	The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study. <i>Cardiology and Therapy</i> , 2021, 10, 189-199.	1.1	8
104	Quantitative Analysis of Atherosclerotic Lesion Composition in Mice. <i>Methods in Molecular Biology</i> , 2006, 319, 137-152.	0.4	8
105	Contributions of young platelets and of previously activated platelets to platelet reactivity in patients with coronary artery disease. <i>Thrombosis Research</i> , 2008, 121, 455-462.	0.8	7
106	Attenuation of apoptosis and the eye of the beholder. <i>Coronary Artery Disease</i> , 2008, 19, 55-58.	0.3	7
107	A Novel Role for Tissue-Type Plasminogen Activator. <i>Circulation</i> , 2008, 118, 1408-1409.	1.6	7
108	Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular disease. <i>Coronary Artery Disease</i> , 2013, 24, 468-474.	0.3	7

#	ARTICLE	IF	CITATIONS
109	Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. <i>Journal of Vascular Surgery</i> , 2018, 67, 279-286.e2.	0.6	7
110	Fc γ RIIIa. <i>Journal of the American College of Cardiology</i> , 2018, 72, 237-238.	1.2	7
111	Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of Fc γ RIIIa. <i>American Journal of Cardiology</i> , 2020, 125, 670-672.	0.7	7
112	Variation in the Ability of Glycoprotein IIb-IIIa Antagonists to Exert and Maintain Their Inhibitory Effects on the Binding of Fibrinogen. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 41-45.	0.8	6
113	Osteoprotegerin is not associated with angiographic coronary calcification. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 177-183.	1.0	6
114	Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation. <i>Coronary Artery Disease</i> , 2009, 20, 175-178.	0.3	6
115	Recent developments in the use of antiplatelet agents to prevent cardiovascular events. <i>Future Cardiology</i> , 2011, 7, 403-413.	0.5	6
116	Variation in platelet expression of Fc γ RIIIa after myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 88-94.	1.0	6
117	Antiplatelet therapy for patients undergoing coronary artery bypass surgery. <i>Kardiologia Polska</i> , 2018, 76, 945-952.	0.3	6
118	The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study. <i>Cardiology and Therapy</i> , 2021, 10, 561-568.	1.1	6
119	Depletion of Systemic Concentrations of Coagulation Factors in Blood From Patients with Atherosclerotic Vascular Disease. <i>Blood</i> , 2011, 118, 1231-1231.	0.6	6
120	Acute Coronary Syndromes: 1. The Platelet's Role. <i>Hospital Practice (1995)</i> , 1998, 33, 171-185.	0.5	5
121	Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. <i>Coronary Artery Disease</i> , 2004, 15, 177-181.	0.3	5
122	Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus. <i>Coronary Artery Disease</i> , 2006, 17, 57-61.	0.3	5
123	Increased platelet expression of Fc γ RIIIa and its potential impact on platelet reactivity in patients with end stage renal disease. <i>Thrombosis Journal</i> , 2007, 5, 7.	0.9	5
124	Prolonged Clotting Time Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 820-821.	1.2	5
125	On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. <i>Coronary Artery Disease</i> , 2007, 18, 405-409.	0.3	4
126	Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 6-9.	1.0	4

#	ARTICLE	IF	CITATIONS
127	Increased local cytokine production at culprit superficial femoral artery plaques. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 293-299.	1.0	4
128	Novel oral anticoagulants in the management of coronary artery disease. <i>Coronary Artery Disease</i> , 2016, 27, 412-419.	0.3	4
129	Surveillance and Management of Troponin Elevation after Vascular Surgery. <i>Annals of Vascular Surgery</i> , 2019, 60, 156-164.	0.4	4
130	Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorbâ„-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. <i>American Heart Journal</i> , 2022, 245, 19-28.	1.2	4
131	Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment. <i>Coronary Artery Disease</i> , 2012, 23, 208-214.	0.3	3
132	Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2016, 27, 185-190.	0.3	3
133	TRimetazidine as an Agent to affect clopidogrel Response: The TRACER Study. <i>Cardiology and Therapy</i> , 2019, 8, 229-237.	1.1	3
134	BARI 2D: A Reanalysis Focusing on Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2249-2262.	1.4	3
135	Current Issues with Glycoprotein IIb/IIIa Antagonists. <i>Current Drug Targets</i> , 2011, 12, 1813-1820.	1.0	2
136	Potential Contribution of Pleiotropic Effects of Direct Anticoagulants to Clinical Benefits. <i>Drug Development Research</i> , 2013, 74, 472-477.	1.4	2
137	Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 297-301.	0.8	2
138	Frequency and safety of switching antithrombin therapy at a regional PCI center. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 282-288.	1.0	1
139	Biomarker profiles as descriptors of left ventricular remodeling after acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011, 22, 311-316.	0.3	1
140	The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study. <i>Cardiology and Therapy</i> , 2020, 9, 493-503.	1.1	1
141	Endothelial Shear Stress and Platelet FcÎ³R1a Expression in Intracranial Atherosclerotic Disease. <i>Frontiers in Neurology</i> , 2021, 12, 646309.	1.1	1
142	Assessing Pharmacodynamic Effects of Antiplatelet Agents With Different Mechanisms of Action. <i>Journal of the American Heart Association</i> , 2021, 10, e020859.	1.6	1
143	Coronary intervention in patients with diabetes, chronic renal disease, and the elderly: therapeutic implications. <i>Reviews in Cardiovascular Medicine</i> , 2007, 8 Suppl 3, S35-41.	0.5	1
144	Acute Coronary Syndromes: 2. Antiplatelet Agents. <i>Hospital Practice (1995)</i> , 1998, 33, 107-130.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Title is missing!. Coronary Artery Disease, 2003, 14, 353-355.	0.3	0
146	Adenosine Diphosphate-Induced Platelet Aggregation Correlates with Platelet Activation Identified with the Use of Flow Cytometry. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 75-79.	0.5	0
147	New antithrombotic agents for the treatment of coronary artery disease. Coronary Artery Disease, 2012, 23, 367.	0.3	0
148	TCT-157 Increased Local Cytokine Production at Culprit Superficial Femoral Artery Plaques. Journal of the American College of Cardiology, 2012, 60, B45-B46.	1.2	0
149	Memorial to Dr Burton E. Sobel. Coronary Artery Disease, 2013, 24, 534.	0.3	0
150	Bivalirudin versus heparin use for patients undergoing PPCI. Lancet, The, 2015, 385, 2044.	6.3	0
151	Use of platelet function testing to guide the timing of coronary artery bypass surgery. Coronary Artery Disease, 2017, 28, 454-456.	0.3	0
152	Platelet Function Testing and Clinical Outcomes. JACC Basic To Translational Science, 2019, 4, 776-777.	1.9	0
153	The Impact of P2Y-Mediated Activation on Release of Angiogenic Proteins by Platelets from Healthy Individuals.. Blood, 2007, 110, 3894-3894.	0.6	0
154	Platelet protagonist/antagonist: understanding the distinguishing characteristics of anticoagulants. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 3, S3-11.	0.5	0
155	Platelet Fc̳R11a Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. , 2022, 2, .		0